Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

American Journal of Nephrology

Volumn 27, Issue 6, 2007, Pages 605-614

  Williams, Mark E ^a   Bolton, W Kline ^b   Khalifah, Raja G ^c   Degenhardt, Thorsten P ^c   Schotzinger, Robert J ^c   McGill, Janet B ^d  

^a JOSLIN DIABETES CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c BioStratum Incorporated   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

Advanced glycation end products; Diabetic nephropathy; Phase 2 clinical studies, pyridoxamine; Pyridoxamine; Serum creatinine; Urinary transforming growth factor beta 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CREATININE; PLACEBO; PYRIDOXAMINE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; STANDARD; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; CREATINE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PYRIDOXAMINE; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 35548975242     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108104     Document Type: Article

References (40)

1. Caramori ML, Mauer M: Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003;12:273-282.
2. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
3. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
4. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
5. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
6. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT-EDIC) Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389.
7. Raj DS, Choudhury D, Welbourne TC, et al: Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis 2000;35:365-380.
8. Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001;38(4 suppl 1):S100-S106.
9. Forbes JM, Cooper ME, Oldfield MD, et al: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003;14(8 suppl 3):S254-S258.
10. Monnier VM, Bautista O, Kenny D, et al: Skin collagen glycation, glycoxidation, and cross-linking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Relevance of glycated collagen products versus HBA 1c as markers of diabetic complications. Diabetes 1999;48:870-880.
11. Genuth S, Sun W, Cleary P, et al: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 2 diabetes. Diabetes 2005;54:3103-3111.
12. Beisswenger PJ, Drummond KS, Nelson RG, et al: Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005;54:3274-3281.
13. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-234.
14. Williams ME: New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003;41(3 suppl 1):S42-S47.
15. Thorpe SR, Baynes JW: Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003;25:275-281.
16. Januszewski AS, Alderson NL, Metz TO, et al: Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 2003;31(Pt 6):1413-1416.
17. Thornalley PJ: Dicarbonyl intermediates in the Maillard reaction. Ann N Y Acad Sci 2005;1043:111-117.
18. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
19. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625.
20. Vlassara H, Striker LJ, Teichberg S, et al: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-11708.
21. Youssef S, Nguyen DT, Soulis T, et al: Effect of diabetes and aminoguanidine therapy on renal advanced glycation end product binding. Kidney Int 1999;55:907-916.
22. Monnier VM: Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 2003;419:1-15.
23. Kelly DJ, Gilbert RE, Cox AJ, et al: Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001;12:2098-2105.
24. Nakamura S, Tachikawa T, Tobita K, et al: An inhibitor of advanced glycation end product formation reduces (carboxymethyl)lysine accumulation in glomeruli of diabetic rats. Am J Kidney Dis 2003;41(suppl 3):S68-S71.
25. Abdel-Rahman E, Bolton WK: Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002;11:565-574.
26. Bolton WK, Cattran DC, Williams ME, et al: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40.
27. Khalifah RG, Baynes JW, Hudson BG: Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999;257:251-258.
28. Metz TO, Alderson NL, Thorpe SR, et al: Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003;419:41-49.
29. Voziyan PA, Hudson BG: Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005;62:1671-1681.
30. Khalifah RG, Chen Y, Wassenberg JJ: Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann N Y Acad Sci 2005;1043:793-806.
31. Degenhardt TP, Alderson NL, Arrington DD, et al: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939-950.
32. Alderson NL, Chachich ME, Frizzell N, et al: Effect of antioxidants and ACE inhibition on chemical modifications of proteins and progression of diabetic nephropathy in the streptozotocin diabetic rat. Diabetologia 2004;47:1385-1395.
33. Zheng F, Leclercq B, Elliot SJ, et al: Reduction of glomerular lesions and albuminuria in db/db mice with established diabetic nephropathy following pyridoxamine treatment (abstract). J Am Soc Nephrol 2002;13:534A.
34. Leclercq B, Zheng F, Berho M, et al: Decreased mortality and albuminuria following pyridoxamine and enalapril therapy in an obese mouse model for type 2 diabetes mellitus with established nephropathy (abstract). J Am Soc Nephrol 2003;14:396A.
35. Zheng F, Zeng YJ, Plati AR, et al: Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 2006;70:507-514.
36. de Zeeuw D, Remuzzi G, Parving HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-2320.
37. Moe SM, Chertow GM, Coburn JW, et al: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-771.
38. Chuang-Stein C: Safety analysis in controlled clinical trials. Drug Inf J 1998;32:1363S-1372S.
39. Degenhardt TP, Grass L, Reddy S, et al: Technical note: the serum concentration of the advanced glycation end product Nε - (carboxymethyl)lysine is increased in uremia. Kidney Int 1997;52:1064-1067.
40. Ziyadeh FN, Hoffman BB, Han DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-8029.